ARCH Venture Management, LLC
About ARCH Venture Management, LLC’s 13F portfolio
ARCH Venture Management, LLC is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , ARCH Venture Management, LLC reported $1.1B across 12 US-listed positions (). Its largest position is PARABILIS MEDICINES INC (PBLS) at 16% of the reported book, and its ten biggest holdings make up 99% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.
| # | Stock | Price | % of portfolio | Shares | Value |
|---|---|---|---|---|---|
| 1 | NASDAQ: PBLS PARABILIS MEDICINES INC | — — | 16% | 6.4M | $175.5M |
| 2 | NASDAQ: BEAM BEAM THERAPEUTICS INC | $20.94 −0.33% | 14% | 4.5M | $155.8M |
| 3 | NASDAQ: RAPP RAPPORT THERAPEUTICS INC | $23.59 +0.81% | 14% | 3.7M | $155.4M |
| 4 | NASDAQ: SPTX SEAPORT THERAPEUTICS INC | — — | 12% | 6.3M | $136.6M |
| 5 | NASDAQ: ERAS ERASCA INC | $14.22 +3.34% | 12% | 7.1M | $129.9M |
| 6 | NASDAQ: VIR VIR BIOTECHNOLOGY INC | $8.87 −3.06% | 12% | 12.7M | $129.4M |
| 7 | NASDAQ: MAZE MAZE THERAPEUTICS INC | $32.43 +3.94% | 11% | 4.1M | $123.0M |
| 8 | NASDAQ: LYEL LYELL IMMUNOPHARMA INC | $13.58 −2.23% | 4.1% | 3.2M | $45.5M |
| 9 | NASDAQ: GENB GENERATE BIOMEDICINES INC | — — | 3.0% | 1.9M | $32.8M |
| 10 | NASDAQ: TXG 10X GENOMICS INC | $57.38 +0.54% | 0.8% | 218K | $8.4M |
| 11 | NASDAQ: BOLD BOUNDLESS BIO INC | $2.38 −0.83% | 0.6% | 2.7M | $6.7M |
| 12 | NASDAQ: GOSS GOSSAMER BIO INC | $11.23 −1.75% | 0.1% | 8.1M | $1.3M |
Showing the 12 largest positions reported in this 13F.
- Healthcare69%
- NewPBLSPARABILIS MEDICINES INC—$175.5M
- NewSPTXSEAPORT THERAPEUTICS INC—$136.6M
- NewBOLDBOUNDLESS BIO INC—$6.7M
- ReducedVIRVIR BIOTECHNOLOGY INC−1.7%$129.4M
- SoldQTTBQ32 BIO INC−100%—
Reading ARCH Venture Management, LLC’s 13F portfolio
ARCH Venture Management, LLC’s $1.1B 13F book is spread across 12 reported positions and is highly concentrated — its ten largest positions alone are 99% of the portfolio. A book this concentrated means a small group of names drives most of its performance. Its five largest positions are PBLS, BEAM, RAPP, SPTX and ERAS, led by PARABILIS MEDICINES INC (PBLS) at 16% of the portfolio. The heaviest sector exposure is Healthcare (69%).
What ARCH Venture Management, LLC changed last quarter
Between 2026-03-31 and Q2 2026, ARCH Venture Management, LLC was a net buyer: it opened 3 new positions and added to 0 more, while trimming 1 and closing 1 outright. Against a 12-name book, that is high turnover, pointing to an active reshuffle of the book. Its largest new or increased position was PARABILIS MEDICINES INC (PBLS), and its biggest reduction was VIR BIOTECHNOLOGY INC (VIR).
What a 13F does and doesn’t reveal
A 13F captures only ARCH Venture Management, LLC’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names ARCH Venture Management, LLC is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.
Frequently asked questions
What is an SEC 13F filing?
A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. ARCH Venture Management, LLC's profile on this page is built directly from those filings.
How current is the 13F data on ARCH Venture Management, LLC's page?
It reflects ARCH Venture Management, LLC's most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When ARCH Venture Management, LLC files its next quarterly report, this page refreshes automatically.
Can I see ARCH Venture Management, LLC's complete list of holdings?
This page highlights ARCH Venture Management, LLC's largest positions rather than all 12 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under ARCH Venture Management, LLC's filings.
Does a 13F show everything ARCH Venture Management, LLC owns?
No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of ARCH Venture Management, LLC's book rather than its full strategy or total assets.
Is 13F data investment advice?
No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why ARCH Venture Management, LLC made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.
Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.

